{"transactions":[{"id":1583768,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-03-11T17:28:46.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof or the parties to the Merger Agreement, each warrant that was outstanding and unexercised immediately prior to the Effective Time, in accordance with its terms, ceased to represent a warrant exercisable for Common Stock and became a warrant exercisable for the Common Stock Merger Consideration that such holder would have been entitled to receive if such warrant had been exercised immediately prior to the Effective Time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III,L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":85750},"source":{"system":"sec-edgar","filing":"0000950170-24-029449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000095017024029449/ownership.xml","form_type":"4"}},{"id":1583767,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-03-11T17:28:46.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":686000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof or the parties to the Merger Agreement, each warrant that was outstanding and unexercised immediately prior to the Effective Time, in accordance with its terms, ceased to represent a warrant exercisable for Common Stock and became a warrant exercisable for the Common Stock Merger Consideration that such holder would have been entitled to receive if such warrant had been exercised immediately prior to the Effective Time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III,L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":686000},"source":{"system":"sec-edgar","filing":"0000950170-24-029449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000095017024029449/ownership.xml","form_type":"4"}},{"id":1583766,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-03-11T17:28:46.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":299430,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof or the parties to the Merger Agreement, each warrant that was outstanding and unexercised immediately prior to the Effective Time, in accordance with its terms, ceased to represent a warrant exercisable for Common Stock and became a warrant exercisable for the Common Stock Merger Consideration that such holder would have been entitled to receive if such warrant had been exercised immediately prior to the Effective Time."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":9.7889,"exercise_date":"2023-03-23","expiration_date":"2031-03-23","underlying":"Common Stock","underlying_shares":299430},"source":{"system":"sec-edgar","filing":"0000950170-24-029449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000095017024029449/ownership.xml","form_type":"4"}},{"id":1583765,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8.000% Series A Redeemable Preferred Stock","published_at":"2024-03-11T17:28:46.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of the Issuer's Series A Redeemable Preferred Stock, par value of $0.0001 per share (\"Series A Preferred Stock\") issued and outstanding was cancelled and the holder thereof was entitled to receive $3,577.77 per share of Series A Preferred Stock in respect of each Series A Preferred Stock determined in accordance with the terms of the Series A Preferred Stock, subject to applicable withholding taxes."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000095017024029449/ownership.xml","form_type":"4"}},{"id":1583764,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T17:28:46.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":395783,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III,L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000095017024029449/ownership.xml","form_type":"4"}},{"id":1583763,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T17:28:46.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1463386,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000095017024029449/ownership.xml","form_type":"4"}},{"id":1754244,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-10-27T16:41:26.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":85750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price is also subject to adjustment pursuant to the Common Stock Warrant issued on October 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III,L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":85750,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":85750},"source":{"system":"sec-edgar","filing":"0000899243-23-020044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000089924323020044/doc4.xml","form_type":"4"}},{"id":1754243,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-10-27T16:41:26.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":686000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price is also subject to adjustment pursuant to the Common Stock Warrant issued on October 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":686000,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":686000},"source":{"system":"sec-edgar","filing":"0000899243-23-020044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000089924323020044/doc4.xml","form_type":"4"}},{"id":1754242,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-27T16:41:26.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":171500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares reflect a 1:10 reverse stock split of the Issuer's Common Stock effective September 1, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III,L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":395783,"source":{"system":"sec-edgar","filing":"0000899243-23-020044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000089924323020044/doc4.xml","form_type":"4"}},{"id":1754241,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":1,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":3,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":4,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93225,"kind":"person","name":"Lathi Vijay K","position":7,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-27T16:41:26.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":1372000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares reflect a 1:10 reverse stock split of the Issuer's Common Stock effective September 1, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1463386,"source":{"system":"sec-edgar","filing":"0000899243-23-020044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000089924323020044/doc4.xml","form_type":"4"}},{"id":2604936,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-12T16:15:15.000Z","date":"2021-01-11","kind":"purchase","acquired":true,"shares":235294,"price":17,"value":3999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, and Vijay K. Lathi are the managers of BPO Management-II (the \"BPO-II Managers\") and may be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":913860,"source":{"system":"sec-edgar","filing":"0000899243-21-032748","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924321032748/doc4.xml","form_type":"4"}},{"id":3434004,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":28626,"price":37.0148,"value":1059585.6648,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1963258,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434003,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":75974,"price":36.5433,"value":2776340.6742,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1991884,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434002,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":78450,"price":36.0911,"value":2831346.795,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2067858,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434001,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":26108,"price":37.0148,"value":966382.3984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1790882,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434000,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":69292,"price":36.5433,"value":2532158.3436,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1816990,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3433999,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":71550,"price":36.0911,"value":2582318.205,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1886282,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3655877,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464281},"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655876,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464281},"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655875,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":1564272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1564272},"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655874,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"purchase","acquired":true,"shares":214285,"price":14,"value":2999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":678566,"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655873,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"purchase","acquired":true,"shares":214286,"price":14,"value":3000004.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2242839,"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655872,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":464281,"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655871,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2028553,"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3655870,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":1,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":3,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93219,"kind":"person","name":"New Leaf Biopharma Opportunities II, L.P.","position":4,"cik":"0001735293","reported_name":"New Leaf Biopharma Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93223,"kind":"person","name":"New Leaf BPO Associates II, L.P.","position":5,"cik":"0001740783","reported_name":"New Leaf BPO Associates II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93224,"kind":"person","name":"New Leaf BPO Management II, L.L.C","position":6,"cik":"0001740755","reported_name":"New Leaf BPO Management II, L.L.C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:33:22.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":1564272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1564272,"source":{"system":"sec-edgar","filing":"0001209191-19-010317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000120919119010317/doc4.xml","form_type":"4"}},{"id":3883196,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":6712986,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":243345},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883195,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":15233315,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":552208},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883194,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":33022786,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1197076},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883193,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":28895188,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1047450},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883192,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":368345,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883191,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2921734,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883190,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":243345,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":243345,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883189,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":552208,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2796734,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883188,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1197076,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2244526,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883187,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1047450,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1047450,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":4197318,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":65997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":372883},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197317,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":198004,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1118722},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197316,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":49505,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":279703},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197315,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":198004,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1118722},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197314,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":148515,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":839110},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197313,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"purchase","acquired":true,"shares":375000,"price":17,"value":6375000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2146308,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197312,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":372883,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1771308,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197311,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":1118722,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1398425,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197310,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":279703,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":279703,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197309,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":1118722,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1957832,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197308,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":839110,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":839110,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}}]}